Effective January 1, 2026, Medi-Cal Rx is excluding coverage for GLP-1 medications prescribed for weight loss: [12] Wegovy, Zepbound, Saxenda: Completely removed from the Contract Drugs List for weight loss Ozempic, Mounjaro, Rybelsus: Restricted to Type 2 diabetes onlyweight loss claims will auto-deny Existing prior authorizations end December 31, 2025 Exceptions: Members under age 21 may still qualify via EPSDT Non-weight-loss indications (Zepbound for OSA, Wegovy for cardiovascular) may still get PA approval This does NOT affect Kaiser commercial or employer-sponsored plansonly Medi-Cal members
Feel Less Nauseous After Your GLP-1 Shot A practical, no-guesswork meal and recovery kit for GLP-1 users who are tired of crackers, skipped meals, and wasted weekends
Who Should Avoid GLP-1 Therapy
2001;163(3 Pt 1):62432
Those with a BMI of 27 or higher and weight-related conditions like high blood pressure or high cholesterol
However, it is crucial to understand that Ozempic is only approved for type 2 diabetes management, not for weight loss
